Growing evidence indicated that NK-1R involved in the occurrence and development of the inflammation-related disease including pneumonia (Weisshaar & Winkelstein, 2014), rheumatoid arthritis (Makino et al., 2012), HIV/SIV encephalitis (Vinet-Oliphant et al., 2010), sepsis (Etogo et al., 2008), asthma (Boot et al., 2007) and skin itching (Costa et al., 2006), etc. These data implied that NK-1R antagonists may be used as therapeutic marker for inflammation-related disease. Here, TACR1 is linked to pneumonia.